| Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition MB Ryan, F Fece de la Cruz, S Phat, DT Myers, E Wong, HA Shahzade, ... Clinical cancer research 26 (7), 1633-1643, 2020 | 339 | 2020 |
| Therapeutic strategies to target RAS-mutant cancers MB Ryan, RB Corcoran Nature reviews Clinical oncology 15 (11), 709-720, 2018 | 335 | 2018 |
| Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK … N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang, LA Kiedrowski, AG Michel, ... Cancer discovery 11 (8), 1913-1922, 2021 | 317 | 2021 |
| Targeting RAS-mutant cancers: is ERK the key? MB Ryan, CJ Der, A Wang-Gillam, AD Cox Trends in cancer 1 (3), 183-198, 2015 | 138 | 2015 |
| Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration KA Williams, M Zhang, S Xiang, C Hu, JY Wu, S Zhang, M Ryan, AD Cox, ... Journal of Biological Chemistry 288 (46), 33156-33170, 2013 | 117 | 2013 |
| GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1–TAB stabilization and regulation of noncanonical NF-κB D Bang, W Wilson, M Ryan, JJ Yeh, AS Baldwin Cancer discovery 3 (6), 690-703, 2013 | 107 | 2013 |
| CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells Z Duan, RY Ames, M Ryan, FJ Hornicek, H Mankin, MV Seiden Cancer chemotherapy and pharmacology 63, 681-689, 2009 | 102 | 2009 |
| USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds B Madan, MP Walker, R Young, L Quick, KA Orgel, M Ryan, P Gupta, ... Proceedings of the National Academy of Sciences 113 (21), E2945-E2954, 2016 | 101 | 2016 |
| A landscape of therapeutic cooperativity in KRAS mutant cancers reveals principles for controlling tumor evolution GR Anderson, PS Winter, KH Lin, DP Nussbaum, M Cakir, EM Stein, ... Cell reports 20 (4), 999-1015, 2017 | 97 | 2017 |
| WNT activates the AAK1 kinase to promote clathrin-mediated endocytosis of LRP6 and establish a negative feedback loop MJ Agajanian, MP Walker, AD Axtman, RR Ruela-de-Sousa, DS Serafin, ... Cell reports 26 (1), 79-93. e8, 2019 | 77 | 2019 |
| KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy MB Ryan, O Coker, A Sorokin, K Fella, H Barnes, E Wong, P Kanikarla, ... Cell reports 39 (12), 2022 | 53 | 2022 |
| ERK/MAPK signaling drives overexpression of the Rac-GEF, PREX1, in BRAF-and NRAS-mutant melanoma MB Ryan, AJ Finn, KH Pedone, NE Thomas, CJ Der, AD Cox Molecular Cancer Research 14 (10), 1009-1018, 2016 | 37 | 2016 |
| CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ... Cell reports 37 (9), 2021 | 22 | 2021 |
| Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression I Sanidas, H Lee, PH Rumde, G Boulay, R Morris, G Golczer, M Stanzione, ... Molecular cell 82 (18), 3333-3349. e9, 2022 | 17 | 2022 |
| The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS-and RAF-Driven Cancers MB Ryan, B Quade, N Schenk, Z Fang, M Zingg, SE Cohen, BM Swalm, ... Cancer Discovery, OF1-OF16, 2024 | 1 | 2024 |
| Abstract A086: NST-628 is a novel molecular glue that inhibits signaling and pathway reactivation in oncogenic RAS-MAPK cancers B Quade, M Ryan, B Swalm, S Cohen, Z Fang, A Ozen, X Huang, AC Dar, ... Molecular Cancer Therapeutics 22 (12_Supplement), A086-A086, 2023 | 1 | 2023 |
| Inhibition of the IL-6-Stat3 pathway and reversal of Taxol and cisplatin resistance in drug resistant ovarian cancer cell lines by a synthetic triterpenoid CDDO-Me Z Duan, R Ames, M Ryan, M Seiden Cancer Research 67 (9_Supplement), 2394-2394, 2007 | 1 | 2007 |
| Abstract ND10: NST-628 is a novel, potent, fully brain-penetrant MAPK pathway molecular glue that inhibits RAS-and RAF-driven cancers MB Ryan, B Quade, N Schenk, Z Fang, M Zingg, SE Cohen, C Li, ... Cancer Research 84 (7_Supplement), ND10-ND10, 2024 | | 2024 |
| Abstract A088: NST-628 is a potent, best-in-class MAPK pathway molecular glue that inhibits RAS-and RAF-driven cancers MB Ryan, N Schenk, M Zingg, M Koehler, B Swalm, B Quade, C Ye, ... Molecular Cancer Therapeutics 22 (12_Supplement), A088-A088, 2023 | | 2023 |
| Abstract A089: NST-628 is a potent, fully brain-penetrant, RAS/MAPK pathway molecular glue inhibitor with efficacy in CNS tumor models MB Ryan, C Li, Y Han, KP Hoeflich, MR Hale, M Hagel Molecular Cancer Therapeutics 22 (12_Supplement), A089-A089, 2023 | | 2023 |
